GLP-1

The World of GLP-1 Agonists: A Game-Changer in Diabetes and Obesity Treatment

by
Ozempic Burnout: The Emotional Cost of Shortcut Weight Loss

GLP-1 receptor agonists have revolutionized diabetes and obesity management, offering new hope for patients worldwide. These drugs mimic the incretin hormone to regulate blood sugar, promote weight loss, and improve cardiovascular health. GLP-1 (Glucagon-Like Peptide-1) Key GLP-1 Agonists in the Market 1. Semaglutide-Based Medications 2. Tirzepatide-Based Medications 3. Other Notable Drugs Ongoing Clinical Trials and … Read more

Sharing is Caring
Share

10 best weight-loss drugs

by
Obesity

1. Zepbound (Tirzepatide) 2. Wegovy (Semaglutide) 3. Mounjaro (Tirzepatide) 4. Saxenda (Liraglutide) 5. Qsymia (Phentermine/Topiramate) 6. Contrave (Naltrexone/Bupropion) 7. Rybelsus (Oral Semaglutide) 8. Xenical (Orlistat) 9. Imcivree (Setmelanotide) 10. Retatrutide (In Trials) Key Considerations: The Verdict For maximum weight loss: Zepbound or Wegovy.For convenience: Rybelsus (oral) or Qsymia.For rare genetic obesity: Imcivree. Always pair medications with diet, exercise, … Read more

Sharing is Caring
Share

Roche Bets $5.3B on Amylin Drug Petrelintide to Shake Up Obesity Market

by
Roche and Zealand Pharma’s $5.3B Obesity Drug Deal: The Science, Strategy, and Shakeup in the Weight-Loss Wars

The obesity drug market, already red-hot from the success of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, just got hotter. In a bold move, Roche and Zealand Pharma announced a $5.3 billion collaboration to develop petrelintide, an amylin-based weight-loss drug poised to challenge the GLP-1 dominance. Here’s a breakdown of the cutting-edge science, the strategic calculus, and the market tremors this deal … Read more

Sharing is Caring
Share

Eli Lilly’s Mounjaro (Tirzepatide) Targets Emerging Markets: A Game-Changer for Global Obesity?

by
he weight loss drug Mounjaro tirzepatide

Eli Lilly and Company, a global pharmaceutical leader, announced plans to launch its blockbuster weight-loss drug Mounjaro (tirzepatide) in emerging markets by late 2024. This strategic move aims to address soaring obesity rates in regions like Latin America, Southeast Asia, and Africa, where demand for effective treatments is surging. With clinical trials showing up to 22.5% body weight … Read more

Sharing is Caring
Share

Understanding the Different Types of Obesity: A Comprehensive Guide

by
Understanding the Different Types of Obesity: A Comprehensive Guide

Obesity is not a one-size-fits-all condition. It manifests in diverse ways, influenced by factors like fat distribution, underlying causes, and metabolic health. Here’s a breakdown of the key types of obesity, their characteristics, and associated risks: 1. By Fat Distribution a. Visceral Obesity (Central/Abdominal Obesity) b. Subcutaneous Obesity 2. By Etiology (Cause) a. Primary Obesity (Simple … Read more

Sharing is Caring
Share

Scientists Discover CD44: A Potential New Weapon Against Obesity

by
Scientists Discover Potential New Weapon Against Obesity

In the relentless battle against obesity, scientists have uncovered a surprising new player: the protein CD44. Groundbreaking research published in The American Journal of Pathology reveals that mice lacking CD44 In the relentless battle against obesity, scientists have uncovered a surprising new player: the protein CD44. Groundbreaking research published in The American Journal of Pathology reveals that mice lacking CD44 remained … Read more

Sharing is Caring
Share

Liraglutide in 2025: Diabetes, Weight Loss, and New Updates

by
Liraglutide Injection

Key Highlights What is Liraglutide? Liraglutide is a GLP-1 receptor agonist, a class of medications revolutionizing type 2 diabetes treatment and weight loss management. Marketed as Victoza for diabetes and Saxenda for obesity, it mimics the GLP-1 hormone to regulate blood sugar and suppress appetite. Approved in the US since 2010, it’s a go-to option … Read more

Sharing is Caring
Share